GLP-1RA are currently being studied in phase 3 trials for the treatment of HFpEF, peripheral artery disease (PAD), diabetic kidney disease (DKD), metabolic liver disorders such as nonalcoholic steatohepatitis (NASH), and neurodegenerative disorders
A clinical trial in 2015 linked an undisclosed GLP-1 to significant improvements in OSA severity, while a 2016 clinical trial found that weight loss resulting from liraglutide was significantly associated with a reduction in the apnea-hypopnea index (AHI)
Youve likely heard buzz (and seen commercials) about GLP-1 drugs for weight management, like semaglutide (Wegovy) or tirzepatide (Zepbound)
To those that have been doing it...better make sure you are following thise cat 2...and im sure cat 3 procedure through USP
This work was led by Frederick Banting, a Canadian surgeon with the support of John McLeod, a physiologist and expert in diabetes
Reviews There are no reviews yet